A review of the efficacy and safety of nanoparticle-based oral insulin delivery systems

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 301, Issue 6, 2011, Pages

  Card, Jeffrey W ^a   Magnuson, Bernadene A ^a  

^a Cantox Health Sciences International   (Canada)

Author keywords

Diabetes; Nanomaterials; Nanotechnology

Indexed keywords

ALGINIC ACID; CHITOSAN; CYANOCOBALAMIN; DEXTRAN; DEXTRAN SULFATE; GLUCOSE; GLYCEROL PALMITOSTEARATE; HYDROXYPROPYLMETHYLCELLULOSE; INSULIN; INSULIN DERIVATIVE; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLY(METHYL METHACRYLATE); POLYGLACTIN; POLYSORBATE 20; STEARIC ACID;

BIOCOMPATIBILITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NANOPARTICLES;

EID: 82455219467     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00107.2011     Document Type: Review

References (55)

1. Babu VR, Patel P, Mundargi RC, Rangaswamy V, Aminabhavi TM. Developments in polymeric devices for oral insulin delivery. Expert Opin Drug Deliv 5: 403-415, 2008.
2. Bhumkar DR, Joshi HM, Sastry M, Pokharkar VB. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. Pharm Res 24: 1415-1426, 2007.
3. Card JW, Magnuson BA. A method to assess the quality of studies that examine the toxicity of engineered nanomaterials. Int J Toxicol 29: 402-410, 2010.
4. Card JW, Jonaitis TS, Tafazoli S, Magnuson BA. An appraisal of the published literature on the safety and toxicity of food-related nanomaterials. Crit Rev Toxicol 41: 22-51, 2011.
5. Carvalho EL, Grenha A, Remuñán-López C, Alonso MJ, Seijo B. Mucosal delivery of liposome-chitosan nanoparticle complexes. Methods Enzymol 465: 289-312, 2009.
6. Chalasani KB, Russell-Jones GJ, Yandrapu SK, Diwan PV, Jain SK. A novel vitamin B(12)-nanosphere conjugate carrier system for peroral delivery of insulin. J Control Release 117: 421-429, 2007.
7. Chalasani KB, Russell-Jones GJ, Jain AK, Diwan PV, Jain SK. Effective oral delivery of insulin in animal models using vitamin B12- coated dextran nanoparticles. J Control Release 122: 141-150, 2007.
8. Chaudhry Q, Scotter M, Blackburn J, Ross B, Boxall A, Castle L, Aitken R, Watkins R. Applications and implications of nanotechnologies for the food sector. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 25: 241-258, 2008.
9. Crane CW, Luntz GR. Absorption of insulin from the human small intestine. Diabetes 17: 625-627, 1968.
10. Cui F, Shi K, Zhang L, Tao A, Kawashima Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J Control Release 114: 242-250, 2006.
11. Cui FD, Tao AJ, Cun DM, Zhang LQ, Shi K. Preparation of insulin loaded PLGA-HP55 nanoparticles for oral delivery. J Pharm Sci 96: 421-427, 2007.
12. Cui F, Qian F, Zhao Z, Yin L, Tang C, Yin C. Preparation, characterization, and oral delivery of insulin loaded carboxylated chitosan grafted poly(methyl methacrylate) nanoparticles. Biomacromolecules 10: 1253-1258, 2009.
13. Damge C, Michel C, Aprahamian M, Couvreur P. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37: 246-251, 1988.
14. Damge C, Vranckx H, Balschmidt P, Couvreur P. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci 86: 1403-1409, 1997.
15. Damge C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release 117: 163-170, 2007.
16. Damge C, Reis CP, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv 5: 45-68, 2008.
17. Elsayed A, Remawi MA, Qinna N, Farouk A, Badwan A. Formulation and characterization of an oily-based system for oral delivery of insulin. Eur J Pharm Biopharm 73: 269-279, 2009.
18. Gholamipour-Shirazi A. Insulin encapsulation. Expert Opin Drug Deliv 5: 1335-1355, 2008.
19. Graf A, Rades T, Hook SM. Oral insulin delivery using nanoparticles based on microemulsions with different structure-types: optimisation and in vitro evaluation. Eur J Pharm Sci 37: 53-61, 2009.
20. Hou ZQ, Zhang ZX, Xu ZH, Zhang H, Tong ZF, Leng YS. The stability of insulin-loaded polybutylcyanoacrylate nanoparticles in an oily medium and the hypoglycemic effect in diabetic rats. Yao Xue Xue Bao 40: 57-64, 2005.
21. ICH. Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. M3(R2). Current Step 4 version dated 11 June 2009. [Online]. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 2009. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/M3_R2/Step4/M3_R2__Guideline.pdf [March 17, 2011].
22. Imran M, Revol-Junelles AM, Martyn A, Tehrany EA, Jacquot M, Linder M, Desobry S. Active food packaging evolution: transformation from micro-to nanotechnology. Crit Rev Food Sci Nutr 50: 799-821, 2010.
23. International Diabetes Foundation. Diabetes Atlas, fourth edition [Online]. Brussels, Belgium: International Diabetes Foundation, 2009. http://www.diabetesatlas.org/[March 17, 2011].
24. Joshi HM, Bhumkar DR, Joshi K, Pokharkar V, Sastry M. Gold nanoparticles as carriers for efficient transmucosal insulin delivery. Langmuir 22: 300-305, 2006.
25. Lin YH, Mi FL, Chen CT, Chang WC, Peng SF, Liang HF, Sung HW. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules 8: 146-152, 2007.
26. Ma Z, Lim TM, Lim LY. Pharmacological activity of peroral chitosaninsulin nanoparticles in diabetic rats. Int J Pharm 293: 271-280, 2005.
27. Mesiha MS, Sidhom MB, Fasipe B. Oral and subcutaneous absorption of insulin poly(isobutylcyanoacrylate) nanoparticles. Int J Pharm 288: 289- 293, 2005.
28. Michel C, Aprahamian M, Defontaine L, Couvreur P, Damge C. The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J Pharm Pharmacol 43: 1-5, 1991.
29. Pan Y, Li YJ, Zhao HY, Zheng JM, Xu H, Wei G, Hao JS, Cui FD. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 249: 139-147, 2002.
30. Qian F, Cui F, Ding J, Tang C, Yin C. Chitosan graft copolymer nanoparticles for oral protein drug delivery: preparation and characterization. Biomacromolecules 7: 2722-2727, 2006.
31. Radwan MA, Aboul-Enein HY. The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats. J Microencapsul 19: 225-235, 2002.
32. Ramesan RM, Sharma CP. Challenges and advances in nanoparticlebased oral insulin delivery. Expert Rev Med Devices 6: 665-676, 2009.
33. Reis CP, Ribeiro AJ, Veiga F, Neufeld RJ, Damgé C. Polyelectrolyte biomaterial interactions provide nanoparticulate carrier for oral insulin delivery. Drug Deliv 15: 127-139, 2008.
34. Reis CP, Veiga FJ, Ribeiro AJ, Neufeld RJ, Damgé C. Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response. J Pharm Sci 97: 5290-5305, 2008.
35. Rekha MR, Sharma CP. Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption. J Control Release 135: 144-151, 2009.
36. Rowe RC, Shesky PJ, Quinn ME, eds. Handbook of Pharmaceutical Excipients, 6th ed. Washington, DC: American Pharmaceutical Association, 2009.
37. Sai P, Damgé C, Rivereau AS, Hoeltzel A, Gouin E. Prophylactic oral administration of metabolically active insulin entrapped in isobutylcyanoacrylate nanocapsules reduces the incidence of diabetes in nonobese diabetic mice. J Autoimmun 9: 713-722, 1996.
38. Sarmento B, Ribeiro A, Veiga F, Ferreira D, Neufeld R. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules 8: 3054-3060, 2007
39. Sarmento B, Martins S, Ferreira D, Souto EB. Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomedicine 2: 743-749, 2007.
40. Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 24: 2198-2206, 2007.
41. Sonaje K, Lin YH, Juang HJ, Wey SP, Chen CT, Sung HW. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 30: 2329-2339, 2009.
42. Sonaje K, Chen YJ, Chen HL, Wey SP, Juang JH, Nguyen HN, Hsu CW, Lin KJ, Sung HW. Enteric-coated capsules filled with freeze-dried chitosan/poly(-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials 31: 3384-3394, 2010.
43. Stern ST, McNeil SE. Nanotechnology safety concerns revisited. Toxicol Sci 101: 4-21, 2008.
44. Sun S, Liang N, Piao H, Yamamoto H, Kawashima Y, Cui F. Insulin-S O (sodium oleate) complex-loaded PLGA nanoparticles: formulation, characterization and in vivo evaluation. J Microencapsul 27: 471-478, 2010.
45. Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev 52: 117-126, 2001.
46. Walker NJ, Bucher JR. A 21st century paradigm for evaluating the health hazards of nanoscale materials? Toxicol Sci 110: 251-254, 2009.
47. Wang T, Wang N, Hao A, He X, Li T, Deng Y. Lyophilization of water-in-oil emulsions to prepare phospholipid-based anhydrous reverse micelles for oral peptide delivery. Eur J Pharm Sci 39: 373-379, 2010.
48. Warheit DB, Sayes CM, Reed KL, Swain KA. Health effects related to nanoparticle exposures: environmental, health and safety considerations for assessing hazards and risks. Pharmacol Ther 120: 35-42, 2008.
49. Watnasirichaikul S, Rades T, Tucker IG, Davies NM. In-vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion. J Pharm Pharmacol 54: 473-480, 2002.
50. Woitiski CB, Carvalho RA, Ribeiro AJ, Neufeld RJ, Veiga F. Strategies toward the improved oral delivery of insulin nanoparticles via gastrointestinal uptake and translocation. BioDrugs 22: 223-237, 2008.
51. Woitiski CB, Neufeld RJ, Veiga F, Carvalho RA, Figueiredo IV. Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur J Pharm Sci 41: 556-563, 2010.
52. Xiong XY, Li YP, Li ZL, Zhou CL, Tam KC, Liu ZY, Xie GX. Vesicles from pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery. J Control Release 120: 11-17, 2007.
53. Yang R, Gao R, Li F, He H, Tang X. The influence of lipid characteristics on the formation, in vitro release, and in vivo absorption of protein-loaded SLN prepared by the double emulsion process. Drug Dev Ind Pharm 37: 139-148, 2011.
54. Zhang N, Ping Q, Huang G, Xu W, Cheng Y, Han X. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm 327: 153-159, 2006.
55. Zhang Z, Lv H, Zhou J. Novel solid lipid nanoparticles as carriers for oral administration of insulin. Pharmazie 64: 574-578, 2009.